Polymer nanoparticles (NPs) represent a promising way to deliver poorly water-soluble anticancer drugs without the use of unwanted excipients, whose presence can be the cause of severe side effects. In this work, a Cremophor-free formulation for paclitaxel (PTX) has been developed by employing PEGylated polymer nanoparticles (NPs) as drug delivery carriers based on modified poly(ε-caprolactone) macromonomers and synthesized through free radical emulsion polymerization. Paclitaxel was loaded in the NPs in a postsynthesis process which allowed to obtain a drug concentration suitable for in vivo use. In vivo experiments on drug biodistribution and therapeutic efficacy show comparable behavior between the NPs and the Cremophor formulation, also showing good tolerability of the new formulation proposed.

PEGylated Nanoparticles Obtained through Emulsion Polymerization as Paclitaxel Carriers

COLOMBO, CLAUDIO;Morbidelli, Massimo;MOSCATELLI, DAVIDE;
2016

Abstract

Polymer nanoparticles (NPs) represent a promising way to deliver poorly water-soluble anticancer drugs without the use of unwanted excipients, whose presence can be the cause of severe side effects. In this work, a Cremophor-free formulation for paclitaxel (PTX) has been developed by employing PEGylated polymer nanoparticles (NPs) as drug delivery carriers based on modified poly(ε-caprolactone) macromonomers and synthesized through free radical emulsion polymerization. Paclitaxel was loaded in the NPs in a postsynthesis process which allowed to obtain a drug concentration suitable for in vivo use. In vivo experiments on drug biodistribution and therapeutic efficacy show comparable behavior between the NPs and the Cremophor formulation, also showing good tolerability of the new formulation proposed.
Breast Cancer; Cremophor; Drug Delivery; Emulsion Polymerization; Nanoparticles; Paclitaxel
File in questo prodotto:
File Dimensione Formato  
2016 - Colombo - Frapolli - Molecular Pharmaceutics - PEGylated Nanoparticles Obtained through Emulsion Polymerization as Paclitaxel Carriers.pdf

Accesso riservato

: Publisher’s version
Dimensione 2.27 MB
Formato Adobe PDF
2.27 MB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11311/972702
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 29
social impact